The rationale for adding serum albumin and AT-III activity to the novel algorithm derive from our pilot study’s observation that they were particularly low among the sickest COVID-19 patients and that the administration of these substances for substitution in the ICU setting surged during the first COVID-19 wave in Germany [19]. The gene discussed is ALB; the disease is COVID-19.